Stero Biotechs to Commence Phase 2 Clinical Trial of ST-AH-01 Cannabidiol Formulation for Ground Breaking Maintenance Therapy and Steroid Reduction in Patients With Autoimmune Hepatitis

BNEI BRAK, Israel, Feb. 28, 2019 /PRNewswire/ — Stero Biotechs has received Ethics Committee approval by Israel’s Ministry of Health and will soon enroll the first patients in a ground-breaking study to use CBD to reduce steroids in patients with liver disease.

Stero discovered that by introducing CBD to patients treated with steroids on regular basis, as their standard of care, allows physicians to lower the dose of the steroids prescribed, and by extension, the steroid’s unwanted harmful side effects. The treatment will also bring back the therapeutic effect to those who are currently resistant and do not respond to steroids treatments.

Stero will commence Phase 2 Clinical Trial of ST-AH-01 Cannabidiol formulation for maintenance therapy and steroid reduction in 15 patients with autoimmune hepatitis in the near future at the Rabin Medical Center, near Tel Aviv.

Autoimmune hepatitis is liver inflammation that occurs when the body’s immune system turns against its own

... read more at: https://www.prnewswire.com/news-releases/stero-biotechs-to-commence-phase-2-clinical-trial-of-st-ah-01-cannabidiol-formulation-for-ground-breaking-maintenance-therapy-and-steroid-reduction-in-patients-with-autoimmune-hepatitis-300803985.html

by

Leave a Reply